Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030
Pharmaceutical Technology
DECEMBER 16, 2022
GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.
Let's personalize your content